In the 1980s, the US National Institutes of Health (NIH) began funding Alzheimer’s Disease Centers throughout the United States in response to the imminent threat of an Alzheimer’s public health problem. Other countries, such as the United Kingdom, made similar commitments of investment. Our understanding of Alzheimer’s has grown as a result of efforts of academic researchers and the pharmaceutical industry to identify treatment approaches and medication to treat the symptoms of the disease.
Still, the disease mystifies us. According to the “2018 Alzheimer’s Disease Facts and Figures,” about 5.7 million Americans are now living with Alzheimer’s dementia. This number is expected to grow to more than 7 million by 2025 and as many as 14 million by 2050.
There are no available treatments to cure or even effectively slow the progression of Alzheimer's Disease. Curing Alzheimer's, while a distant lofty goal, is the only way to decrease the burden of this disease on families and communities. Meanwhile, the research and medical community must work together to identify evidence-based practices that reduces the burden of this disease. Collaborative care models will prove beneficial once tried and tested in a variety of settings.
Below is a roundup of literature on Alzheimer's Disease.
Blood test for toxic amyloid may detect Alzheimer's 8 years before symptoms, study says (Alzheimer's News Today)
Long-term SSRI use may slow progression to Alzheimer's Dementia (American Psychiatric Association)